mnl777 jili
SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Wolfspeed, Inc. (NYSE: WOLF) securities between August 16, 2023 and November 6, 2024. Wolfspeed is a global semiconductor company focused on silicon carbide materials and the fabrication of devices for power applications. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Wolfspeed, Inc (WOLF) Misled Investors Regarding its Revenue Projections According to the complaint, defendants provided the public with revenue projections that depended on the Mohawk Valley fabrication facility ramping its production to meet and/or exceed demand for its 200mm wafer product. Defendants provided these overwhelmingly positive statements to investors while, at the same time, concealing material adverse facts concerning the true state of Wolfspeed’s growth potential and, in particular, the operational status and profitability of the Mohawk Valley fabrication facility. First, to meet its publicly stated projections, the Company would have to cancel or otherwise indefinitely suspend planned future projects such as the facility in Saarland, Germany. Second, the Company would have to terminate a significant portion of its workforce (approximately 20%) and shutter the Durham fabrication facility. Plaintiff alleges that on November 6, 2024, Wolfspeed announced its financial results for the first quarter of fiscal year 2025 and unveiled guidance for the second quarter well below expectations. While defendants had repeatedly claimed that 20% utilization of the Mohawk Valley fabrication facility would result in $100 million revenue out of the facility, defendants now guided to a range 30% to 50% below that mark. The Company attributed its results and lowered guidance to “demand ... ramp[ing] more slowly than we originally anticipated” as “EV customers revise their launch time lines as the market works though this transition period.” On this news, Wolfspeed’s stock price fell from $13.71 per share on November 6, 2024, to $8.33 per share on November 7, 2024, a decline of about 39.24%. What Now: You may be eligible to participate in the class action against Wolfspeed, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by January 17, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Wolfspeed, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6e2a3cda-6c15-4240-9c27-2fcf37e35629Porter shot 9 for 12 (4 for 6 from 3-point range) and 4 of 4 from the free-throw line for the Blue Raiders (5-1). Essam Mostafa scored 20 points and added 10 rebounds. Kamari Lands shot 6 for 12, including 4 for 8 from beyond the arc to finish with 17 points. The Bulls (3-3) were led in scoring by Jayden Reid, who finished with 18 points, four assists and three steals. Jamille Reynolds added 17 points and nine rebounds for South Florida. Kasen Jennings finished with 13 points. Middle Tennessee led 51-33 at halftime, with Porter racking up 14 points. Mostafa led the way with a team-high 14 second-half points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
None
The Miami Dolphins ' final injury report of the week before their clash with the New York Jets saw the word "questionable" used more than fans would like. However, one player who's been on the report for weeks is finally set to play on Sunday. Starting CB Kendall Fuller has cleared concussion protocol, as evidenced by him practicing in full and avoiding a game status designation for Sunday. Fuller has been out for the last three games after suffering his second concussion of the season during the Dolphins' 23-15 win over the Los Angeles Rams last month. He missed Miami's wins over New England and Las Vegas as well as last Thursday's loss to Green Bay. His return comes at a key moment, as depth is a question at the position right now with Cam Smith going on injured reserve and nickel corner Kader Kohou dealing with a back injury that has him listed as questionable for Sunday. Speaking of questionable, Miami has seven players listed as questionable for Sunday, including OLBs Bradley Chubb and Cameron Goode, who returned to practice this week as they attempt to return from the PUP list. T Terron Armstead is also questionable, but he's managed to play so far this year without hardly practicing for much of it, so there's plenty of reason to believe he'll play on Sunday On the other side of the coin, the New York Jets will likely be without star CB Sauce Gardner and RB Breece Hall, a big blow on both sides of the ball to the Jets. Both players are listed as doubtful for the game, with LB C.J. Mosley having been ruled out. The Dolphins and Jets get underway on Sunday at 1:00 pm ET from Hard Rock Stadium in Miami Gardens. This article first appeared on A to Z Sports and was syndicated with permission.
Are international thieves exploiting tourist visas to target pro-athletes' homes?
Dry AMD Market Size in the 7MM was ~ USD 1,300 million in 2023, estimated DelveInsight 11-25-2024 11:14 PM CET | Health & Medicine Press release from: ABNewswire DelveInsight's "Dry AMD Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Dry AMD, historical and forecasted epidemiology as well as the Dry AMD market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover Key Insights into the Dry AMD Market with DelveInsight's In-Depth Report @ Dry AMD Market Size [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Key Takeaways from the Dry AMD Market Report * In November 2024:- Stealth BioTherapeutics Inc.- A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD). * In November 2024:- Cognition Therapeutics- This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD. * The total prevalent cases of AMD in the 7MM was nearly 68,347,900 in 2023. * Among the 7MM, the US accounted for the highest prevalent cases of dry AMD in 2023, with around 20,970,000 cases; these cases are expected to increase during the forecast period. * Several researchers reported a declining prevalence of late AMD in the United States when comparing data from the 2000s with data gathered in previous decades. * In 2023, the geographical atrophy accounted for nearly 955,900 cases in EU4 and the UK. * According to the estimates, in Japan, it is observed that age-specific cases of geographic atrophy were most prevalent in the 85+ years age group, accounting for over 40% of total cases in 2023. * The leading Dry Age-Related Macular Degeneration Companies such as Alkeus Pharmaceuticals, Novartis, Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics , and others. * Promising Dry Age-Related Macular Degeneration Therapies such as Iptacopan (LNP023), ALK-001, RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104 , and others. Stay ahead in the Dry AMD Therapeutics Market with DelveInsight's Strategic Report @ Dry AMD Market Outlook [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Dry AMD Epidemiology Segmentation in the 7MM * total prevalent cases of AMD, * stage-specific prevalent cases of AMD, * total prevalent cases of geographic atrophy, * total prevalent cases of dry AMD, * total diagnosed prevalent cases of dry AMD, * age-specific cases of early and intermediate AMD, * age-specific cases of geographic atrophy, * geographic atrophy cases by visual impairment Download the report to understand which factors are driving Dry AMD epidemiology trends @ Dry AMD Prevalence [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Marketed Dry Age-related Macular Degeneration Drugs IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio IZERVAY, also known as avacincaptad pegol is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. By inhibiting the formation of complement system terminal fragments, IZERVAY may decrease the activation of inflammasomes and the formation of membrane attack complexes (MAC), which occur at the end of the complement cascade. In August 2023, the US FDA approved IZERVAY for the treatment of geographic atrophy secondary to AMD. Concurrently, Astellas Pharma announced that the European Medicines Agency (EMA) has accepted Iveric Bio's MAA for avacincaptad pegol for the treatment of geographic atrophy secondary to AMD. SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals SYFOVRE is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. The company is evaluating pegcetacoplan in several clinical studies, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), complement-dependent nephropathies (CDN). SYFOVRE is the first and only approved therapy for geographic atrophy secondary to AMD. In January 2024, the CHMP of the EMA adopted a negative opinion on the MAA of intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to AMD. Emerging Dry Age-related Macular Degeneration Drugs * Iptacopan (LNP023): Novartis Novartis Pharmaceuticals is developing Iptacopan, an oral small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, FB inhibitor LNP023 binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as intermediate age-related macular degeneration (iAMD), C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), etc. Recently, in December 2023, the US FDA approved FABHALTA (ipatocan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH) (Novartis, 2023). Currently, the company is investigating iptacopan in the Phase II trial (NCT05230537) for the treatment of patients with early and intermediate age-related macular degeneration. * ALK-001: Alkeus Pharmaceuticals Allegro Ophthalmics is developing risuteganib (also known as ALG-1001), a breakthrough integrin-regulating therapy for ocular health that reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib helps reduce the cellular burden of oxidative stress and restores retinal homeostasis. Research suggests that risuteganib interferes with integrin functions that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress. Currently, the company has received the US FDA agreement under Special Protocol Assessment (SPA) for Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative age-related macular degeneration (dry AMD). Moreover, the overall protocol design of Phase IIb/III dry AMD clinical trial was finalized by the US FDA. Get In-Depth Knowledge on Dry AMD Market Trends and Forecasts with DelveInsight @ Dry AMD Treatment Market [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Dry AMD Market Outlook Geographic atrophy, the advanced stage of dry AMD, has emerged as a prominent focus of research. Current investigations predominantly center on therapies targeting complement inhibitors of C3 and C5, pivotal factors in triggering inflammation and subsequent cell death within the eye. Extensive studies led by the National Eye Institute and esteemed researchers globally have unveiled the likelihood of an overactive complement system as a central player in the genesis of dry AMD and its evolution toward GA. Enhancing comprehension of the pathophysiology of geographic atrophy resulting from dry AMD can benefit patients, optometrists, and ophthalmologists alike. This improved understanding could lead to more accurate identification and diagnosis of patients, potentially lessening the burden of the disease and extending their visual function over time. Dry AMD Drugs Market Integrin inhibitor have been effective in several preclinical models, and promising results have been reported thus far from clinical trials. Indeed, most of the current avSs3 clinical investigations centre on treating eye diseases (age-related macular degeneration (AMD) using topically dosed or intravitreally injected small molecules and peptides, although these molecules also inhibit other av integrins and/or a5Ss1 to varying degrees. The molecules that have progressed the furthest in the clinic are risuteganib (Luminate, Allegro Ophthalmics). It is a small peptide integrin regulator protecting cells of the human RPE against dysfunction related to oxidative stress. With age, decreased mitochondrial oxidative phosphorylation increases the generation of reactive oxygen species and decreased metabolic activity, thus negatively affecting cellular bioenergetics and mitochondrial functioning. It is also known that RPE mitochondrial dysfunction contributes to the oxidative stress causing AMD. Unlock Strategic Insights with DelveInsight's Comprehensive Dry AMD Market Report @ Dry AMD Market Drivers and Barriers [ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Scope of the Dry AMD Market Report * Coverage- 7MM * Dry AMD Companies- Alkeus Pharmaceuticals, Novartis, Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others. * Dry Age-Related Macular Degeneration Therapies- Iptacopan (LNP023), ALK-001, RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others. * Dry AMD Therapeutic Assessment: Dry AMD Current marketed and Lipodystrophy Emerging Therapies * Dry AMD Market Dynamics: Dry AMD Market drivers and Dry AMD Market Barriers Table of Content 1. Key Insights 2. Executive Summary 3. Dry Age-Related Macular Degeneration Competitive Intelligence Analysis 4. Dry Age-Related Macular Degeneration Market Overview at a Glance 5. Dry Age-Related Macular Degeneration Disease Background and Overview 6. Dry Age-Related Macular Degeneration Patient Journey 7. Dry Age-Related Macular Degeneration Epidemiology and Patient Population 8. Dry Age-Related Macular Degeneration Treatment Algorithm, Current Treatment, and Medical Practices 9. Dry Age-Related Macular Degeneration Unmet Needs 10. Key Endpoints of Dry Age-Related Macular Degeneration Treatment 11. Dry Age-Related Macular Degeneration Marketed Products 12. Dry Age-Related Macular Degeneration Emerging Therapies 13. Dry Age-Related Macular Degeneration Seven Major Market Analysis 14. Attribute Analysis 15. Dry Age-Related Macular Degeneration Market Outlook (7 major markets) 16. Dry Age-Related Macular Degeneration Access and Reimbursement Overview 17. KOL Views on the Dry Age-Related Macular Degeneration Market 18. Dry Age-Related Macular Degeneration Market Drivers 19. Dry Age-Related Macular Degeneration Market Barriers 20. Appendix 21. DelveInsight Capabilities About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=dry-amd-market-size-in-the-7mm-was-usd-1300-million-in-2023-estimated-delveinsight ] Phone: 09650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/case-study/in-licensing-opportunity This release was published on openPR.
No. 8 Kentucky flying high ahead of Western Kentucky meetingA former Allianz fund manager was spared prison time on Friday over his role in a meltdown of private investment funds sparked by the Covid-19 pandemic that caused an estimated $7 billion of investor losses. Gregoire Tournant, 57, of Basalt, Colorado, pleaded guilty in June to two counts of investment adviser fraud. He agreed to give up $17.5 million in ill-gotten gains, including bonuses that were inflated by his fraud. Chief Judge Laura Taylor Swain of the federal court in Manhattan sentenced him to 18 months home confinement and three years probation. Tournant’s defence lawyers had urged Swain to spare him prison time, citing health issues. They also said Tournant had expressed remorse and called the case less serious than the typical investment adviser fraud scheme. “We are deeply appreciative to the Court for imposing this just sentence and recognising that incarceration was not appropriate in this case,” defence lawyers Seth Levine and Daniel Alonso said in a statement. Prosecutors with the US attorney’s office in Manhattan had recommended that Tournant be sentenced to at least seven years in prison. They argued that more than 100 investors in Tournant’s funds lost billions of dollars when they collapsed and that he continued to minimize the importance of what he had done. The case stemmed from the March 2020 collapse of the German insurer’s now-defunct Structured Alpha funds, which Tournant had created and oversaw as chief investment officer. In May 2022, Allianz agreed to pay more than $6 billion and its US asset management unit pleaded guilty to securities fraud to resolve government probes into the collapse. Two other former Allianz fund managers pleaded guilty at the time. The Structured Alpha funds had bet heavily on stock options, in a manner designed to limit losses in a market selloff, which Tournant likened to a form of insurance. Prosecutors said Tournant misled investors about the funds’ risks by altering performance data and diverging from his promised hedging strategy and obstructed a US Securities and Exchange Commission probe by directing a colleague to lie. The funds once had more than $11 billion of assets under management, but lost about $7 billion in February and March 2020 as the start of the pandemic set off a worldwide market panic. Prosecutors said the fraud ran from 2014 through March 2020, with Tournant being paid more than $60 million over that time.
A NEW speeding rule that comes into effect on January 6 will see drivers face more risk of getting a ticket. Motorists across Des Moines, Iowa , will have to be extra cautious as a host of mobile speed cameras are to be installed. New signs, as required by state law , have already been put in place - months after the city's mobile speed cameras were taken out of action. A new state law requiring DOT approval for their locations and saw cameras shut down, causing cars in the area to recklessly speed. Speaking to KCCINews, Megan Rapp, a Des Moines homeowner, said: "Cars that are driving really fast, definitely going over 25 mph. "I've seen cars go as fast as 50 mph on the street." Read more Motors News But recently, the state approved roughly a dozen locations for the cameras across the city, including the 4300 block of Ingersoll where Rapp and her two sons live. Des Moines police are now in the process of installing new signs at these spots in a bid to alert drivers of the traffic enforcement cameras in the area. Once the signs are in place, police will give warnings from December 2, while enforcement will begin on January 6 and will see the smallest fines increase from $65 to $75. Sgt. Paul Parizek of the Des Moines Police said: "We just don't have the resources to put a cop on every corner. Most read in Motors “We don't have the resources to stick a cop in front of every park or every school. "So this is us working smarter and using the technology to our advantage. “And hopefully, we'll get that compliance that we're looking for so that the kids are safe when they ride their bikes or walk to school." This comes as traffic lights could be given a major facelift with a fourth color added - as driving practices change with advances in technology. Already the motoring industry is becoming ever-dominiated by electric and autonomous vehicles, with the use of self-driving cars becoming steadily more common. To this end, experts from North Carolina State University are proposing the addition of a fourth "white light" to traffic signals - which will instruct human drivers to "follow the car in front of them." The "white light" would signal human drivers to follow autonomous vehicles, which in turn would use the networked capabilities of AVs to ultimately reduce traffic delays and improve fuel efficiency. Elsewhere, drivers in one US state will need to make an extra $1,000 to afford gas prices next year , an expert has warned. The surge in prices is set to be triggered by a move requiring gas stations to carry a more expensive blend fuel.
What Is DreamLLM? Everything You Need to Know About the Learning Framework
I’m a Celebrity 2024 elimination: which stars have made it to Celebrity Cyclone? 2024 line-up
Texas Tech 78, New Orleans 70
2 / 10 Mortgage rates are suddenly going up again. Why? Mortgage rates are suddenly going up again. Why? Mortgage rates are back up to almost 7% in a reversal of some of the declines in recent months, pointing to growing concerns about future inflation. The 30-year-fixed rate jumped to 6.90% last week, up from 6.86% a week earlier and its highest level since July, according to data from the Mortgage Bankers Association released Wednesday. Despite the increase, overall mortgage loan application volume ticked up by 1.7% on a weekly basis. Read More 3 / 10 The 2 biggest stock market risks in 2025, according to Goldman Sachs The 2 biggest stock market risks in 2025, according to Goldman Sachs As 2024 comes to a close, the U.S. stock market has posted considerable returns on a red-hot rally led by major technology stocks that have benefited from artificial intelligence. But Goldman Sachs ( GS ) is warning of two major risks that could put a damper on the stock market party in 2025. Read More 4 / 10 You can earn crypto without actually buying or selling it. Here’s how You can earn crypto without actually buying or selling it. Here’s how Cryptocurrency investment has become an increasingly popular avenue for generating income and building long-term financial security. However, earning through cryptocurrencies doesn’t always require active buying and selling. In fact, there are several indirect methods to earn cryptocurrencies that involve minimal ongoing effort. These strategies allow individuals to generate passive income—earnings that require little to no continuous labor, energy, or time for maintenance. Read More 5 / 10 Trump Media is close to buying a cryptocurrency trading platform Trump Media is close to buying a cryptocurrency trading platform President-elect Donald Trump’s social media company is reportedly in advanced negotiations to acquire the cryptocurrency trading platform Bakkt, according to a report by the Financial Times on Monday late afternoon. The publication cited two individuals familiar with the matter. Read More 6 / 10 Bitcoin breaks through $94,000 for the first time — and it’s getting less volatile Bitcoin breaks through $94,000 for the first time — and it’s getting less volatile Bitcoin passed $94,000 for the first time following reports that President-elect Donald Trump’s media company could be close to buying a cryptocurrency trading platform. Additionally, earlier this week , several Bitcoin ETFs began trading on the Nasdaq, offering investors a new way to gain exposure to Bitcoin without directly owning the cryptocurrency. Read More 7 / 10 The S&P 500 is about to have a big 2025, Goldman Sachs says — even without the ‘Magnificent 7' The S&P 500 is about to have a big 2025, Goldman Sachs says — even without the ‘Magnificent 7' After Morgan Stanley’s ( MS ) bullish outlook, another financial giant has joined the optimistic chorus for the S&P 500 in 2025. What’s more, it expects the growth of the S&P 500 to occur without relying on the outperformance of the Magnificent Seven, marking a notable shift in market dynamics. Read More 8 / 10 The stock market risks of Nvidia’s success, according to a strategist The stock market risks of Nvidia’s success, according to a strategist Off English Andrew Krei, co-chief investment officer of Crescent Grove Advisors, breaks down Nvidia earnings expectations 9 / 10 Target just had its biggest earnings miss in years — and the stock plummets 21% to a 1-year-low Target just had its biggest earnings miss in years — and the stock plummets 21% to a 1-year-low Target’s ( TGT ) price cuts and early holiday promotions aren’t delivering the expected results . Target stock plummeted by more than 21% on Wednesday morning after it reported disappointing third-quarter earnings . Despite slashing prices on thousands of items and seeing a slight uptick in customer traffic, inflation-weary shoppers are holding back on purchases. Read More 10 / 10LOS ANGELES – Two-time Cy Young Award winner Blake Snell says it was a really easy decision to sign with the World Series champion Los Angeles Dodgers and the presence of three-time MVP Shohei Ohtani played a part, too. Snell was introduced Tuesday at Dodger Stadium accompanied by his agent Scott Boras. The left-hander finalized a $182 million, five-year contract last Saturday. Recommended Videos “It was really easy just cause me and Haeley wanted to live here, it’s something we’ve been talking about for a while,” Snell said, referring to his girlfriend. “Then you look at the team. You look at what they’ve built, what they’re doing. It’s just something you want to be a part of.” Last month, Snell opted out of his deal with San Francisco to become a free agent for the second consecutive offseason after he was slowed by injuries during his lone year with the San Francisco Giants. Snell gets a $52 million signing bonus, payable on Jan. 25, and annual salaries of $26 million, of which $13.2 million each year will be deferred . Because Snell is a Washington state resident, the signing bonus will not be subject to California income tax. “It just played out the way that people around me felt comfortable with, I felt comfortable with, they felt comfortable with,” Snell said. “We talked and found something that could work for both of us. You want your worth, you want your respect, and you want enough time to where you can really make a name for yourself. I've made a name for myself outside of LA, but I'm going to be invested.” Two-way star Ohtani, who signed a record $700 million, 10-year deal a year ago, had a historic first season with the Dodgers. He helped them win the franchise's eighth World Series while playing only as designated hitter and became MVP in the National League for the first time after twice winning the award while in the American League. “It helps with him in the lineup for sure. That’s big motivation,” Snell said. “You want to be around players like that when you’re trying to be one of the best in the game. Yeah, it played a big part.” Snell joins Ohtani and fellow Japanese right-hander Yoshinobu Yamamoto atop Los Angeles’ rotation. All-Star Tyler Glasnow will be back after having his first season in LA derailed by a sprained elbow. Ohtani didn’t pitch this year while recovering from right elbow surgery but is expected back on the mound in 2025. The rest of the rotation includes Tony Gonsolin, Landon Knack, Dustin May, Bobby Miller and Emmet Sheehan. “I pitched on six-man, five-man, four-man rotations,” Snell said. “I'm good with it all as long as we have a plan, we'll execute it.” Snell, who turns 32 on Wednesday, went 5-3 with a 3.12 ERA in 20 starts this year, throwing a no-hitter at Cincinnati on Aug. 2 for one of only 16 individual shutouts in the major leagues this season. He struck out 145 and walked 44 in 104 innings. He was sidelined between April 19 and May 22 by a strained left adductor and between June 2 and July 9 by a strained left groin. Snell won Cy Young Awards in 2018 with Tampa Bay and 2023 with San Diego. He is 76-58 with a 3.19 ERA in nine seasons with the Rays (2016-20), Padres (2021-23) and Giants. He has known Andrew Friedman, Dodgers president of baseball operations, since he was 18. In the aftermath of winning the World Series and discussing how the Dodgers could repeat next year, Friedman said, “All conversations kept coming back to Blake.” “Usually in major league free agency, you're buying the backside of a guy's career, the accomplishments that they have had,” he said. “With Blake, one thing that's really exciting for us is, as much success as he's had, we feel like there's more in there." Snell was 2-2 against the Dodgers in his career. “We couldn’t beat him, so we’re going to have him join us,” Friedman said. .___ AP MLB: https://apnews.com/hub/MLB
The TOI Entertainment Desk is a dynamic and dedicated team of journalists, working tirelessly to bring the pulse of the entertainment world straight to the readers of The Times of India. No red carpet goes unrolled, no stage goes dark - our team spans the globe, bringing you the latest scoops and insider insights from Bollywood to Hollywood, and every entertainment hotspot in between. We don't just report; we tell tales of stardom and stories untold. Whether it's the rise of a new sensation or the seasoned journey of an industry veteran, the TOI Entertainment Desk is your front-row seat to the fascinating narratives that shape the entertainment landscape. Beyond the breaking news, we present a celebration of culture. We explore the intersections of entertainment with society, politics, and everyday life. Read More Anikha Surendran shines in blue elegance How to make South Indian-style Ghee Roast Eggs for dinner Aditi Rao Hydari's bridal look continues to steal the spotlight 8 healthiest sources of selenium 9 best sources of calcium other than milk Tamannaah Bhatia works her denim magic in a chic bodycon dress 10 most remote tourist destinations to explore this new year From Rashmika Mandanna to Samantha Ruth Prabhu: Best celeb-inspired lehengas for South Indian brides 9 baby girl names that mean beauty in SanskritCHICAGO (AP) — Blackhawks general manager Kyle Davidson passed the point of no return following a 4-2 loss to Boston on Wednesday night. That's when he decided to replace coach Luke Richardson. “I don’t think once you cross that threshold in your own mind, you can go back,” Davidson said. “And so I crossed that point after the Boston game the other night.” The aftermath of that decision began in earnest on Friday, when Chicago practiced for the first time under interim coach Anders Sorensen — a day after the Richardson move was announced by the organization. The big task for Sorensen is turning around a team that wasn't exactly built for a playoff run this season, but one Davidson feels is better than its NHL-worst 8-16-2 record. The offensively challenged Blackhawks have lost four in a row and eight of 10 overall going into Saturday's game against Winnipeg. “I don’t believe this is a last-place group. And that’s where we find ourselves,” Davidson said in his first media session since Richardson was fired. “Do I believe we deserve better in some games that we didn’t get a point or two points out of this year? Yes. But dissect that. Why didn’t we get those points? I feel like there were things that could be cleaned up. And maybe some things kept popping up here and there that, again, probably should have been improved upon.” Richardson, 55, had a 57-118-15 record in two-plus seasons with Chicago. The coaching change comes with the Blackhawks set to host the Winter Classic on Dec. 31 against the St. Louis Blues at Wrigley Field. In a statement released by the team, Richardson said he was grateful for the opportunity to coach the Blackhawks and wished the team and its fans the best for the rest of the season. Sorensen, 49, was the head coach at Rockford in the AHL before he got the interim job, making him a familiar face for many of the Blackhawks. He was hired by the organization as a development coach ahead of the 2013-14 season. He joined the IceHogs staff as an assistant coach beginning in 2018-19. Sorensen becomes the first Swedish-born head coach in NHL history. “I think for me, I’ve been a big believer in where my two feet are is where I’m going to work and try to get better and we’ll see what happens,” Sorensen said. “Obviously, like you said, you want to strive to improve and get up to higher levels. It’s surreal right now, trying to digest.” Asked what he needs to do to secure the job long-term, a chuckling Sorensen responded: “Win games.” “We want to see progress with a lot of our younger players,” he continued. “We want to make sure we’re kind of building off this and progressing and that’s the biggest thing.” Connor Bedard’s development has always been the most important part of this season for Chicago, and it seemed as if his progress had stalled a bit with Richardson in charge — at least offensively. The No. 1 overall pick in the 2023 draft has five goals and 14 assists in 26 games after he had 11 goals and 10 assists at the same point last season. While he has been more responsible defensively, the 19-year-old Bedard and the Blackhawks were hoping for more offensive production in his second year. “He’s one of those guys we have to get him up the ice and get skating,” Sorensen said. “That’s when he’s at his best. We all see what he can do when the puck’s on his stick. We have to get a way for him to get the puck in motion. That’s the biggest thing right now.” Bedard called Richardson “a really good guy” and said he was sad seeing him go. But he also was looking forward to working with Sorensen. “It’s good to have the first skate and get comfortable and talk to him,” Bedard said. “It’s good we all know him a little bit from being at training camps and stuff like that, so it was a good first day.” While Bedard attracts the most attention, Chicago's offensive trouble runs a lot deeper than its young center. The Blackhawks signed Tyler Bertuzzi and Teuvo Teravainen in free agency , and the two forwards have combined for just 11 goals and 11 assists. Chicago is averaging 2.42 goals per game, ranked No. 31 in the NHL ahead of only Nashville going into Friday night’s games. The Blackhawks finished with a league-low 178 goals last season. “Everyone needs to take ownership of this,” captain Nick Foligno said. “The sad part is one person maybe takes the fall, but it’s all of us that need to be better in here. We’re excited to get to work with Anders, and I think Luke would want us to forge ahead, too. He cares a lot about this group and this organization so the best we can do is get moving ahead here and show we can be that team.” AP NHL: https://apnews.com/hub/nhl
Former UFC middleweight champion Israel Adesanya has shed light on his retirement plans, acknowledging that his illustrious fighting career may soon be coming to an end. ‘The Last Stylebender,’ now 35, last competed at UFC 305 in August, where he suffered a fourth-round submission loss to South African middleweight champion Dricus du Plessis. The bout marked Adesanya’s first since losing his title in a shock decision defeat to Sean Strickland a year earlier. Speaking on the FLAGRANT Podcast, Adesanya reflected on his achievements in the sport and hinted at a possible timeline for his retirement. “I’ve said this already, with what I’ve already done in this game, a lot of people don’t even get to the belt, get to the UFC,” he stated. “I’ve done it twice. Still the only two-time UFC middleweight champion.” Related News Adesanya to headline UFC event in Saudi Usman warns young prospect who called out Adesanya UFC: Adesanya ‘insulted’ by Magomedov challenge Adesanya admitted he remains unbooked for a return to the Octagon but has been linked to a potential clash with Nassourdine Imavov at UFC Saudi Arabia next year. While he still has ambitions to achieve more in the sport, he is also realistic about the toll it takes. “You’ve got to break up with fighting before fighting breaks up with you,” Adesanya explained. “When will I? I don’t know... I’m 35 now. I know I’m over the halfway point and I’m definitely a few years away, maybe three years away. But who knows? I know I don’t want to be fighting at 40.” Despite the uncertainty, Adesanya remains proud of his journey, having captured the middleweight belt twice—an accomplishment that cements his legacy as one of the sport’s greats. “If what I’ve already done won’t make me happy, what will? I’m happy but I’m not content,” he said, hinting at a few more goals he wishes to achieve before stepping away from the cage.
World Athletics considering a World Treadmill ChampionshipsNone